51345-97-2

Upstream product

• 88-60-8 2-tert-Butyl-5-methylphenol 
• 14472-14-1 4-bromo-3-methylphenol 
• 75-65-0 tert-butyl alcohol 

Downstream Products

• 207737-00-6 1-Bromo-5-tert-butyl-4-(2-methoxy-ethoxymethoxy)-2-methyl-benzene 
• 856253-13-9 3-bromo-5-tert-butyl-6-hydroxy-2-methyl-benzaldehyde 
• 1433065-10-1 C₁₈H₂₅BrO₄ 
• 1433065-04-3 C₁₉H₂₇BrO₄ 
• 1433064-98-2 C₁₄H₁₉BrO₂ 
• 1433065-22-5 C₁₈H₂₇IO₃ 
• 1433065-16-7 C₁₈H₂₇BrO₄ 
• 197915-39-2 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-[4-(2-hydroxy-ethoxy)-phenyl]-6-phenethyl-5,6-dihydro-pyran-2-one 
• 197915-44-9 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-(4-methoxy-phenyl)-5,6-dihydro-pyran-2-one 
• 197915-43-8 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-(4-hydroxy-phenyl)-6-[2-(4-hydroxy-phenyl)-ethyl]-5,6-dihydro-pyran-2-one 
• 197915-36-9 3-(2-tert-Butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-[2-(3-hydroxy-phenyl)-ethyl]-6-phenyl-5,6-dihydro-pyran-2-one 
• 197915-35-8 3-(2-tert-butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-[2-(4-hydroxy-phenyl)-ethyl]-6-phenyl-5,6-dihydro-pyran-2-one 
• 197915-37-0 6-[2-(4-aminophenyl)ethyl]-3-(2-tert-butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-4-hydroxy-6-phenyl-5,6-dihydro-pyran-2-one 
• 197915-48-3 6-[2-(4-Amino-phenyl)-ethyl]-3-(2-tert-butyl-4-hydroxymethyl-5-methyl-phenylsulfanyl)-6-cyclohexyl-4-hydroxy-5,6-dihydro-pyran-2-one 

Relevant academic research and scientific papers

Novel chiral biphenyl quaternary ammonium salt phase transfer catalyst and preparation method and application thereof

The invention discloses a novel chiral biphenyl quaternary ammonium salt phase transfer catalyst and a preparation method and application thereof. The catalyst comprises a compound A and a compound B.The molecular structure of the compound A is shown as a

PHENOXYMETHYL DERIVATIVES

The invention provides novel compounds having the general formula (I), wherein RA, RB, RC, RC1 and W are as defined herein, compositions including the compounds and methods of using the compounds.

Novel biphenyl organocatalysts for iminium ion-catalyzed asymmetric epoxidation

Two novel chiral biphenyl iminium salts derived from L-acetonamine, containing electron-withdrawing 3,30-substituents on the biphenyl unit, have been prepared and tested as asymmetric catalysts for epoxidation of prochiral alkenes. The results are compared with those achieved using the corresponding unsubstituted system.

Asymmetric induction via short-lived chiral enolates with a chiral C-O axis

A novel method has been developed for the asymmetric cyclization of alkyl aryl ethers. The reactions were assumed to proceed via short-lived chiral enolate intermediates with a chiral C-O axis to give cyclic ethers with tetrasubstituted carbon in up to 99% ee. The half-life of racemization of the chiral enolate intermediate was roughly estimated to be ～1 s at -78 C.

New chiral phase-transfer catalysts possessing a 6,6′-bridged ring on the biphenyl unit: Application to the synthesis of α,α-dialkyl- α-amino acids

A new chiral phase-transfer catalyst possessing a 6,6′-bridged ring on the biphenyl unit has been developed for the practical synthesis of α,α-dialkyl-α-amino acids. This catalyst shows very high activity for the asymmetric alkylation of an alanine deriva

METHODS FOR TREATING RETINOID RESPONSIVE DISORDERS USING SELECTIVE INHIBITORS OF CYP26A AND CYP26B

The invention provides methods for treating an individual having a retinoid responsive disorder. In one embodiment, a method involves administering to the individual an effective amount of a selective CYP26B inhibitor, the selective CYP26B inhibitor having at least 10-fold selectivity for CYP26B relative to CYP26A. In another embodiment, a method involves administering to the individual an effective amount of a selective CYP26A inhibitor, the selective CYP26A inhibitor having a chemical formula set forth in the specification. The invention further provides screening methods for identifying a selective CYP26A inhibitor or selective CYP26B inhibitor.

COMPOUNDS HAVING SELECTIVE CYTOCHROME P450RAI-1 OR SELECTIVE CYTOCHROME P450RAI-2 INHIBITORY ACTIVITY AND METHODS OF OBTAINING THE SAME

Compounds of formulas 1 through 17 provided in the specification specifically or selectively inhibit either the cytochrome P450RAI-1 enzyme or the cytochrome P450RAI-2 enzyme.